22987-10-6

Basic information

• Product Name: Propanamide,N-(3-aminophenyl)-
• Synonyms: 3'-Aminopropionanilide;N-(3-Aminophenyl)propionamide;m-Aminopropionanilide
• CAS NO: 22987-10-6
• Molecular Formula: C₉H₁₂N₂O
• Molecular Weight: 164.2044
• EINECS: 245-369-0
• Product Categories: Intermediates of Dyes and Pigments;Aromatic Carboxylic Acids, Amides, Anilides, Anhydrides & Salts;Amides;Carbonyl Compounds;Organic Building Blocks
• Mol File: 22987-10-6.mol
• Article Data: 10

Chemical Properties

• Melting Point: 92-96℃
• Boiling Point: 392.028 °C at 760 mmHg
• Flash Point: 190.892 °C
• Appearance: /
• Density: 1.162 g/cm³
• Vapor Pressure: 2.36E-06mmHg at 25°C
• Refractive Index: 1.616
• PKA: 14.82±0.70(Predicted)
• CAS DataBase Reference: Propanamide,N-(3-aminophenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Propanamide,N-(3-aminophenyl)-(22987-10-6)
• EPA Substance Registry System: Propanamide,N-(3-aminophenyl)-(22987-10-6)

Safety Data

• Hazard Codes: Xi:Irritant
• Statements: R36/37/38:
• Safety Statements: S26:; S36:
• WGK Germany: 3
• Hazardous Substances Data: 22987-10-6(Hazardous Substances Data)

Usage

General Description

Propanamide,N-(3-aminophenyl)-, also known as N-(3-aminophenyl)propanamide, is a chemical compound with the molecular formula C9H11NO. It is a derivative of propanamide, and its structure consists of a propanamide group attached to an aminophenyl group. It is used in the synthesis of pharmaceuticals and organic compounds, particularly in the development of new drugs. Propanamide,N-(3-aminophenyl)- may have medicinal properties and could potentially be used as a therapeutic agent, although further research and clinical studies would be needed to confirm its effectiveness and safety for medical use.

InChI:InChI=1/C9H12N2O/c1-2-9(12)11-8-5-3-4-7(10)6-8/h3-6H,2,10H2,1H3,(H,11,12)

Upstream product

• 99-09-2 3-nitro-aniline 
• 79-03-8 propionyl chloride 
• 108-45-2 m-phenylenediamine 
• 7470-50-0 N-(3-nitrophenyl)propionamide 

Downstream Products

• 59517-27-0 2-Chloro-N-(3-propionylamino-phenyl)-benzamide 
• 28023-04-3 N-[3-(3-Ethyl-ureido)-phenyl]-propionamide 
• 41402-28-2 3'-propionamidophenyl-S-t-butylthiolcarbamate 
• 59683-81-7 m-propionamido-acetylacetanilide 
• 78580-78-6 N-[3-(3-keto-5,5-dimethylcyclohexenyl)amino] phenyl propionamide 
• 129882-11-7 N-[3-(Butyl-phenethyl-amino)-phenyl]-propionamide 
• 56968-03-7 N-[2-(2-Cyano-4,6-dinitro-phenylazo)-5-diethylamino-phenyl]-propionamide 
• 56935-81-0 N-[2-(2-Bromo-4,6-dinitro-phenylazo)-5-diethylamino-phenyl]-propionamide 
• 94510-18-6 N-[2-(2,6-Dicyano-4-nitro-phenylazo)-5-diethylamino-phenyl]-propionamide 
• 85929-33-5 (E)-N-(2-((2-bromo-6-cyano-4-nitrophenyl)diazenyl)-5-(diethylamino)phenyl)propionamide 
• 22185-75-7 N,N-diethyl-N'-propionyl-1,3-benzenediamine 
• 129882-17-3 N-(3-butylaminophenyl)propionamide 
• 25218-78-4 N-[3-(3-Isopropyl-ureido)-phenyl]-propionamide 
• 56418-08-7 2-Ethyl-hexanoic acid (3-propionylamino-phenyl)-amide 

Relevant articles and documents

Discovery of novel quinazoline derivatives as potent PI3Kδ inhibitors with high selectivity

Inhibition of PI3Kδ has been proved to be an efficacious strategy for the treatment of hematological malignancies where the PI3K/Akt signaling pathway is hyperactive. Herein, a series of quinazoline derivatives bearing acrylamide fragment were prepared using skeleton-deconstruction strategy. The preliminary bioactivity evaluation resulted in the discovery of lead compound 15c. Compound 15c exhibited excellent enzyme activity against PI3Kδ (IC50 = 27.5 nM) compared with BEZ235 as well as the significant anti-proliferation activities. With the high selectivity over other PI3K isoforms and potent effects on PI3K/Akt pathway, 15c can be identified as a promising PI3Kδ inhibitor worthy of further profiling.

Heteroaromatic compound and application thereof to drug

The invention discloses a heteroaromatic compound and application thereof to drug. In particular, the invention provides a heteroaromatic compound or stereoisomers thereof, geometric isomers, tautomers, racemates, nitrogen oxides, hydrates, solvates, metabolites, pharmaceutically acceptable salts or prodrugs thereof, and a pharmaceutical composition comprising the compound provided by the invention. The invention also discloses application of the compound provided by the invention or the pharmaceutical composition thereofto preparation of a medicine for reatment of autoimmune diseases or proliferative diseases.

Reactive dyestuffs comprising a triazine moiety and a vinylsulfonyl moiety both being linked by a substituted alkylene bridge member

A reactive dye of the formula STR1 in which: F is a radical selected from the group consisting of metal-free or metal-containing monoazo or disazo dyes containing at least one --SO3 H group, anthraquinone dyes, sulfophthalocyanine dyes, formazan dyes, phenazine dyes, oxazine dyes and nitroaryl dyes, R is hydrogen, C1 -C4 alkyl which is unsubstituted or substituted with --COOH or --SO3 H, cyanoethyl, or hydroxyethyl, X is fluorine, chlorine, bromine, --SO3 H, phenylsulfonyl or C1 -C4 -alkylsulfonyl, p is 1 or 2 and A is a radical of the formula STR2 in which: Y is chlorine, bromine, fluorine, --OH, --OSO3 H, --O-acyl, --CN, --COOH, --COO--C1 -C4 -alkyl, --CONH2 or --SO2 --Z, the group designated "alk" is a straight or branched polymethylene radical having 2 to 6 carbon atoms, V is STR3 hydrogen or C1 -C4 -alkyl which is unsubstituted or substituted by C1 -C2 -alkoxy, carboxyl, sulfo, halogen or hydroxy, Z is β-halogenoethyl, vinyl or β-acetoxyethyl, or A is a radical of the formulae STR4 in all of which R' is C1-6 -alkyl or hydrogen, Z is as defined above, o is 0 to 6, and m is 2 to 6.